Rapidly progressing dementia as a manifestation of the Creutzfeldt-Jakob disease: an analysis of two cases
DOI:
https://doi.org/10.15584/ejcem.2019.1.15Keywords:
14-3-3 protein, brain biopsy, cerebrospinal fluid, Creutzfeldt-Jakob disease, EEG, prionAbstract
Introduction. Creutzfeldt-Jakob disease (CJD) is a rare and fatal neurodegenerative disease of the central nervous system which is caused by an infectious protein called prion. Multiple forms of CJD have been classified including sporadic (more than 90% cases), familial, iatrogenic and variant type of disease. CJD, especially in its early stages, is a highly challenging illness to diagnose.
Aim. Article aims to present cases of Creutzfeldt-Jackob disease with early symptoms of rapidly progressing dementia at the initial stage of CJD.
Description of the cases. This paper describes two cases of patients with suspected CJD with a history of rapidly progressive dementia admitted to the Department of Neurology, MSWiA Hospital in Rzeszów.
Conclusion. Despite the fact that CJD is an incurable illness and there is no cure guaranteeing recovery, it is important to make the right diagnosis. Assay of 14-3-3 protein in cerebrospinal fluid is a sensitive and specific marker which is helpful in the diagnosis of CJD. The only relevant method of correctly confirming a diagnosis of this disease is by performing a brain biopsy.
Downloads
References
Liberski PP. Pasażowalne encefalopatie gąbczaste. Warszawa: Centrum Upowszechniania Nauki PAN; 1999.
Creutzfeldt HG. Übereineeigenartigeherdförmige Erkrankung des Zentralnervensystems. Z Ges Neurol Psychiatr. 1920;57:1-18.
Krasnianski A, Kaune J, Jung K, Kretzschmar HA, Zerr I. First symptom and initial diagnosis in sporadic CJD patients in Germany. J Neurol. 2014;261(9):1811-1817.
Segarra C, Lehmann S, Coste J. Prion protein expression and processing in human mononuclear cells: the impact of the codon 129 prion genepolymorphism. PLoS One. 2009;4(6):e5796.
Gambetti P, Dong Z, Yuan J, et al. A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol. 2008;63(6):697-708.
Atarashi R, Satoh K, Sano K, et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med. 2011;17:175-78.
Parchi P, Strammiello R, Notari S, et al. Incidence and spectrum of sporadic Creutzfeldt-Jakob disease variants with mixed phenotype and co-occurrence of PrPSc type: an updates classification. Acta Neuropathol. 2009;118(5):659-71.
Bratosiewicz-Wąsik J, Smoleń-Dzirba J, Rozemuller AJ, et al. Association between the PRNP 1368 polymorphism and the occurrence of sporadic Creutzfeldt-Jakob disease. Prion. 2012;6(4):413-416.
Zerr I, Bodemer M, Gefeller O, et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt-Jakob disease. Ann Neurol. 1998;43(1):32-40.
Brown P, Gibbs CJ, Rodgers-Johnson P, et al. Human spongiform encephalopathy: the National Institutes of Health series of 300 cases of experimentally transmitted disease. Ann Neurol. 1994;35:513-529.
Wadsworth JD, Hill AF, Beck JA, Collinge J. Molecular and clinical classification of human prion disease. Br Med Bull. 2013;66:241-254.
National Creutzfeldt-Jakob Disease Surveillance Diagnostic Criteria. National Creutzfeldt-Jakob Disease Surveillance 2010. Address: http://www.cjd.ed.ac.uk
Zerr I, Kallenber K, Summers DM, et al. Updated clinical diagnostic criteria for sporadic Creutzfeldt-Jakob disease. Brain. 2009;132(Pt 10):2659-2668.
Chaudhari D, Renjen PN, Zutshi D, Ahmad K, Kumar A. An intriguing case of rapidly progressive dementia: Creutzfeldt–Jakob Disease. Apollo Med. 2017;14:234-237.
Coulthart MB, Jansen GH, Olsen E, et al. Diagnostic accuracy of cerebrospinal fluid protein markers for sporadic Creutzfeldt-Jakob disease in Canada: a 6-year prospective study. BMC Neurol. 2011;11:133.
Yegya-Raman N, Aziz R, Schneider D, Tobia A, Leitch M, Nwobi O. A Case of Sporadic Creutzfeldt-Jakob Disease Presenting as Conversion Disorder. Case Rep Psychiatry. 2017;2017:2735329.
Hamlin C, Puoti G, Berri S, et al. A comparison of tau and 14-3-3 protein in the diagnosis of Creutzfeldt-Jakob disease. Neurology. 2012;79(6):547-552.
Peckeu L, Delasnerie-Lauprètre N, Brandel JP, et al. Accuracy of diagnosis criteria in patients with suspected diagnosis of sporadic Creutzfeldt-Jakob disease and detection of 14-3-3 protein, France, 1992 to 2009. Euro Surveill. 2017;22(41). doi: 10.2807/1560-7917.ES.2017.22.41.16-00715.
Binelli S, Agazzi P, Canafoglia L, et al. Myoclonus in Creutzfeldt-Jakob disease: polygraphic and video-electroencephalography assessment of 109 patients. Mov Disord. 2010;25(16):2818-2827.
Steinhoff BJ, Zerr I, Glatting M, Schulz-Schaeffer W, Poser S, Kretzschmar HA. Diagnostic value of periodic complexes in Creutzfeldt-Jakob disease. Ann Neurol. 2004;56(5):702-708.
Schröter A, Zerr I, Henkel K, Tschampa HJ, Finkenstaedt M, Poser S. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt-Jakob disease. Arch Neurol. 2000;57(12):1751-1757.
Macfarlane RG, Wroe SJ, Collinge J, Yousry TA, Jäger HR. Neuroimaging findings in human prion disease. J Neurol Neurosurg Psychiatry. 2007;78(7):664-670.
Louie JK, Gavali SS, Belay ED, et al. Barriers to Creutzfeldt-Jakob disease autopsies, California. Emerg Infect Dis. 2004;10(9):1677-1680.
Vitali P, Maccagnano E, Caverzasi E, et al. Diffusion-weighted MRI hyperintensity patterns differentiate CJD from other rapid dementias. Neurology. 2011;76(20):1711-1719.
Kojima G, Tatsuno BK, Inaba M, Velligas S, Masaki K, Liow KK. Creutzfeldt-Jakob disease: a case report and differential diagnoses. Hawaii J Med Public Health. 2013;72(4):136-139.
Kobayashi A, Matsuura Y, Iwaki T, et al. Sporadic Creutzfeldt-Jakob Disease MM1+2C and MM1 are Identical in Transmission Properties. Brain Pathol. 2016;26(1):95-101.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
